

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Bydureon 2 mg prolonged-release suspension for injection in pre-filled pen.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each pre-filled pen delivers a dose of 2 mg of exenatide in 0.85 mL.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Prolonged-release suspension for injection in pre-filled pen (BCise).

White to off-white opaque suspension.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Bydureon is indicated in adults, adolescents and children aged 10 years and above with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control.

For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5, and 5.1.

4.2 Posology and method of administration

Posology

The recommended dose is 2 mg exenatide once weekly.

Patients switching from immediate-release exenatide (Byetta) to prolonged-release exenatide (Bydureon or Bydureon BCise) may experience transient elevations in blood glucose concentrations, which generally improve within the first four weeks after initiation of therapy. Patients switching between the prolonged-release exenatide products (Bydureon or Bydureon BCise) may do so, with no expected relevant effect on blood glucose concentrations.

When prolonged-release exenatide is added to existing metformin and/or thiazolidinedione therapy, the current dose of metformin and/or thiazolidinedione can be continued. When added to sulphonylurea therapy, a reduction in the dose of sulphonylurea should be considered to reduce the risk of hypoglycaemia (see section 4.4). Combination therapy with thiazolidinedione was only studied in adult patients.

Prolonged-release exenatide should be administered once a week on the same day each week. The day of weekly administration can be changed if necessary as long as the last dose was administered at least three days before. Prolonged-release exenatide can be administered at any time of day, with or without meals.

If a dose is missed, it should be administered as soon as practical, provided the next regularly scheduled dose is due in 3 days or more. Thereafter, patients can resume their usual once weekly dosing schedule.

If a dose is missed and the next regularly scheduled dose is due 1 or 2 days later, the patient should not administer the missed dose, but instead resume prolonged-release exenatide on the next regularly scheduled dosing day.

The use of this medicinal product does not require additional self-monitoring. Blood glucose self-monitoring is necessary to adjust the dose of sulphonylurea and of insulin, particularly when prolonged-release exenatide therapy is started and insulin is reduced. A stepwise approach to insulin dose reduction is recommended.

If a different glucose-lowering treatment is started after the discontinuation of prolonged-release exenatide, consideration should be given to the prolonged release of the product (see section 5.2).

Special populations

Elderly

No dose adjustment is required based on age. However, as renal function generally declines with age, consideration should be given to the patient's renal function (see Renal impairment) (see section 5.2).

Renal impairment

No dose adjustment is necessary for patients with mild or moderate renal impairment.

Prolonged-release exenatide is not recommended for use in patients with end-stage renal disease or severe renal impairment (glomerular filtration rate [GFR] < 30mL/min) (see section 4.4).

Hepatic impairment

No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).

Paediatric population

No dose adjustment is required for adolescents and children aged 10 years and above. No data are available for children below 10 years of age (see sections 5.1 and 5.2).

Method of administration

Subcutaneous use

Prolonged-release exenatide is for self-administration by the patient. Each pen can only be used by one person and is for single use.

Prior to initiation of prolonged-release exenatide, it is strongly recommended that patients and caregivers be trained by their healthcare professional. The “Instructions for the User”, provided in the carton, must be followed carefully.

Each dose should be administered in the abdomen, thigh, or the back of the upper arm as a subcutaneous injection immediately after the medicinal product is fully mixed.

When used with insulin, prolonged-release exenatide and insulin must be administered as two separate injections.

For instructions on the preparation of the medicinal product before administration, see section 6.6 and the “Instructions for the User”.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Prolonged-release exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Prolonged-release exenatide is not a substitute for insulin. Diabetic ketoacidosis has been reported in insulin-dependent patients after rapid discontinuation or dose reduction of insulin (see section 4.2).

Prolonged-release exenatide must not be administered by intravenous or intramuscular injection.

Renal impairment

In patients with end-stage renal disease receiving dialysis, single doses of immediate release exenatide increased frequency and severity of gastrointestinal adverse reactions; therefore, prolonged-release exenatide formulations are not recommended for use in patients with end-stage renal disease or severe renal impairment (GFR < 30mL/min).

There have been uncommon events of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsened chronic renal failure and acute renal

failure, sometimes requiring haemodialysis. Some of these events occurred in patients experiencing events that may affect hydration, including nausea, vomiting, and/or diarrhoea and/or receiving medicinal products known to affect renal function/hydration status. Concomitant medicinal products included angiotensin converting enzymes inhibitors, angiotensin-II antagonists, non-steroidal anti-inflammatory medicinal products and diuretics. Reversibility of altered renal function has been observed with supportive treatment and discontinuation of potentially causative medicinal products, including exenatide.

Severe gastrointestinal disease

Prolonged-release exenatide has not been studied in patients with severe gastrointestinal disease, including gastroparesis. Its use is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting, and diarrhoea. Therefore, the use of this medicinal product is not recommended in patients with severe gastrointestinal disease.

Acute pancreatitis

Use of GLP-1 receptor agonists has been associated with a risk of developing acute pancreatitis. In clinical studies of Bydureon BCise, acute pancreatitis occurred in 0.4% of patients. There have been spontaneously reported events of acute pancreatitis with prolonged-release exenatide. Resolution of pancreatitis has been observed with supportive treatment, but very rare cases of necrotising or haemorrhagic pancreatitis and/or death have been reported. Patients should be informed of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. If pancreatitis is suspected, the use of this medicinal product should be discontinued; if acute pancreatitis is confirmed, it should not be restarted. Caution should be exercised in patients with a history of pancreatitis.

Concomitant medicinal products

The concurrent use of prolonged-release exenatide formulations with D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied. The concurrent use of a formulation of prolonged-release and immediate-release exenatide has not been studied and is not recommended.

Lack of efficacy due to anti-drug antibodies (ADA) in paediatric patients

Paediatric patients are possibly more prone to developing high titers of ADA than adults (see section 4.8). Patients with higher titre antibodies may have an attenuated HbA_{1c} response.

No commercial testing of anti-drug antibodies is available, but if targeted glycaemic control is not achieved despite confirmed patient compliance, regardless of the reason for the lack of efficacy, physicians should consider alternative antidiabetic therapy.

Interaction with warfarin

There have been spontaneously reported cases of increased INR (International Normalized Ratio), sometimes associated with bleeding, with concomitant use of warfarin and exenatide (see section 4.5).

Hypoglycaemia

The risk of hypoglycaemia was increased when prolonged-release exenatide was used in combination with a sulphonylurea in clinical studies. Furthermore, in the clinical studies, patients on a sulphonylurea combination with mild renal impairment had an increased incidence of hypoglycaemia compared to patients with normal renal function. To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea should be considered.

Rapid weight loss

Rapid weight loss at a rate of > 1.5 kg per week has been reported in patients treated with exenatide. Weight loss of this rate may have harmful consequences. Patients with rapid weight loss should be monitored for signs and symptoms of cholelithiasis.

Discontinuation of treatment

After discontinuation, the effect of prolonged-release exenatide may continue as plasma levels of exenatide decline over 10 weeks. Choice of other medicinal products and dose selection should be considered accordingly, as adverse reactions may continue and efficacy may, at least partly, persist until exenatide levels decline.

4.5 Interaction with other medicinal products and other forms of interaction

Sulphonylureas

The dose of a sulphonylurea may require adjustment due to the increased risk of hypoglycaemia associated with sulphonylurea therapy (see sections 4.2 and 4.4).

Gastric emptying

The results of a study using paracetamol as a marker of gastric emptying suggest that the effect of prolonged-release exenatide to slow gastric emptying is minor and not expected to cause clinically significant reductions in the rate and extent of absorption of concomitantly administered oral medicinal products. Therefore, no dose adjustments for medicinal products sensitive to delayed gastric emptying are required.

When 1,000 mg paracetamol tablets were administered, either with or without a meal, following 14 weeks of prolonged-release exenatide therapy, no significant changes in paracetamol AUC were observed compared to the control period. Paracetamol C_{max} decreased by 16% (fasting) and 5% (fed) and t_{max} was increased from approximately 1 hour in the control period to 1.4 hours (fasting) and 1.3 hours (fed).

The following interaction studies have been conducted using 10 mcg immediate-release exenatide but not prolonged-release exenatide:

Warfarin

A delay in t_{max} of about 2 h was observed when warfarin was administered 35 min after immediate-release exenatide. No clinically relevant effects on C_{max} or AUC were observed. Increased INR has been spontaneously reported during concomitant use of warfarin and prolonged-release exenatide. INR should be monitored during initiation of prolonged-release exenatide therapy in patients on warfarin and/or coumarin derivatives (see sections 4.4 and 4.8).

Hydroxy methyl glutaryl coenzyme A reductase inhibitors

Lovastatin AUC and C_{max} were decreased approximately 40% and 28%, respectively, and t_{max} was delayed about 4 h when immediate-release exenatide was administered concomitantly with a single dose of lovastatin (40 mg) compared with lovastatin administered alone. In 30-week placebo-

controlled clinical studies with immediate-release exenatide, concomitant use of exenatide and HMG CoA reductase inhibitors was not associated with consistent changes in lipid profiles (see section 5.1). No predetermined dose adjustment is required; however, lipid profiles should be monitored as appropriate.

Digoxin and lisinopril

In interaction studies of the effect of immediate-release exenatide on digoxin and lisinopril there were no clinically relevant effects on C_{max} or AUC, however a delay in t_{max} of about 2 h was observed.

Ethinyl estradiol and levonorgestrel

Administration of a combination oral contraceptive (30 mcg ethinyl estradiol plus 150 mcg levonorgestrel) one hour before immediate-release exenatide did not alter the AUC, C_{max} or C_{min} of either ethinyl estradiol or levonorgestrel. Administration of the oral contraceptive 35 minutes after exenatide did not affect AUC but resulted in a reduction of the C_{max} of ethinyl estradiol by 45%, and C_{max} of levonorgestrel by 27-41%, and a delay in t_{max} by 2-4 h due to delayed gastric emptying. The reduction in C_{max} is of limited clinical relevance and no adjustment of dosing of oral contraceptives is required.

Paediatric population

Interaction studies with exenatide have only been performed in adults.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Due to the long washout period of prolonged-release exenatide, women of childbearing potential should use contraception during treatment with prolonged-release exenatide. This medicinal product should be discontinued at least 3 months before a planned pregnancy.

Pregnancy

There are no adequate data from the use of prolonged-release exenatide in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Prolonged-release exenatide should not be used during pregnancy and the use of insulin is recommended.

Breast-feeding

It is unknown whether exenatide is excreted in human milk. Prolonged-release exenatide should not be used during breast-feeding.

Fertility

No fertility studies in humans have been conducted.

4.7 Effects on ability to drive and use machines

Prolonged-release exenatide has minor influence on the ability to drive and use machines. When prolonged-release exenatide is used in combination with a sulphonylurea, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines.

4.8 Undesirable effects

Summary of the safety profile

The most frequent adverse reactions during the clinical studies in adults were gastrointestinal-related (mainly nausea (8%), which tended to dissipate with continued treatment), headache (4%) and injection site reactions, such as injection site pruritus (3%) and injection site erythema (2%). In addition, hypoglycaemia with a sulphonylurea occurred very commonly (see Description of selected adverse reactions, below). Most adverse reactions were mild to moderate in intensity.

Tabulated list of adverse reactions

The frequency of adverse reactions of Bydureon BCise identified from clinical studies in adults are summarised in Table 1 below.

The pooled clinical studies data set for Bydureon BCise comprises two phase 3 comparator-controlled studies of 6 to 12 months duration in adults. The follow-up and extension phases of studies are included in the pool. Background therapies included diet and exercise alone or with metformin, a sulphonylurea, a thiazolidinedione or a combination of oral glucose-lowering medicinal products. Adverse reactions that have been observed with the prolonged-release exenatide but not in clinical studies with Bydureon BCise are also included in Table 1.

Background therapies in the prolonged-release exenatide clinical trials included diet and exercise, metformin, a sulphonylurea, a thiazolidinedione, a combination of oral glucose-lowering agents or a basal insulin.

The reactions are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$) very rare ($< 1/10,000$) and not known (cannot be estimated from the available data).

Table 1: Adverse reactions of Bydureon BCise identified from clinical studies and spontaneous reports in adults

System organ class /adverse reaction terms	Frequency of occurrence ¹					
	Very common	Common	Uncommon	Rare	Very rare	Not known
Blood and lymphatic system disorders						
Drug-induced thrombocytopenia ⁹						X
Hepatobiliary disorders						
Cholecystitis ¹¹			X			
Cholelithiasis			X			
Immune system disorders						
Anaphylactic reaction ²				X		
Metabolism and nutrition disorders						
Hypoglycaemia (with a sulphonylurea) ^{5,6,7}	X					
Hypoglycaemia (without a sulphonylurea) ^{5,6,7}			X			
Hypoglycaemia (with insulin) ^{3,4,5}		X				
Decreased appetite			X			
Dehydration			X			
Nervous system disorders						
Headache		X				
Dizziness		X				
Dysgeusia			X			
Somnolence ²			X			
Gastrointestinal disorders						
Nausea ⁵		X				
Diarrhoea		X				
Vomiting		X				
Constipation		X				
Dyspepsia		X				
Gastroesophageal reflux disease		X				
Abdominal distension		X				
Abdominal pain		X				
Flatulence			X			
Acute pancreatitis (see section 4.4)			X			
Eructation ²			X			
Intestinal obstruction ²			X			
Delayed gastric emptying ¹⁰			X			
Skin and subcutaneous tissue disorders						
Urticaria			X			
Hyperhidrosis			X			
Macular or papular rash			X			
Pruritus			X			
Alopecia ²			X			

System organ class /adverse reaction terms	Frequency of occurrence ¹					
	Very common	Common	Uncommon	Rare	Very rare	Not known
Angioedema ⁹						X
Injection site abscesses and cellulitis ⁹						X
Renal and urinary disorders						
Altered renal function ⁸			X			
General disorders and administration site conditions						
Injection site pruritus ⁵		X				
Injection site erythema ⁵		X				
Fatigue		X				
Injection site reaction ⁵			X			
Asthenia			X			
Injection site rash ⁵			X			
Feeling jittery ²				X		
Investigations						
International normalised ratio increased ⁹ (see section 4.4)						X

¹ Rate based on completed long-term safety and efficacy studies (n = 526), unless other indicated. Includes follow-up within seventy days of the last dose received and extension period.

² Rate based on twelve prolonged-release exenatide completed long-term efficacy and safety studies n = 2868 total.

³ Based on hypoglycaemic events that 1. Result in loss of consciousness, seizure, or coma which resolves after administration of glucagon or glucose OR 2. Require third-party assistance to resolve because of impairment in consciousness or behaviour and has glucose value of < 54 mg/dL (3 mmol/L) OR 3. Result in symptoms consistent with hypoglycaemia with a concomitant glucose < 54 mg/dL (3 mmol/L) prior to treatment.

⁴ Frequency reported from the 28-week controlled treatment period of the prolonged-release exenatide as add on to insulin glargine study (N=231).

⁵ See Description of selected adverse reactions section, below.

⁶ Frequencies reported in pooled data from the controlled periods of the two phase 3 clinical studies (n = 410).

⁷ Based on hypoglycaemic events that have symptoms consistent with hypoglycaemia with a concomitant glucose value of < 54 mg/dL (3 mmol/L) prior to treatment.

⁸ Includes acute renal failure, worsened chronic renal failure, renal impairment, increased serum creatinine. See section 4.4.

⁹ Rate based on prolonged-release exenatide spontaneous reports data (unknown denominator).

¹⁰ Rate based on sixteen prolonged-release exenatide completed long term efficacy and safety studies n = 4086 total.

¹¹ Rate based on BYDUREON completed safety and efficacy studies (n=3560 total); includes DURATION 7 and DURATION 8 studies.

Description of selected adverse reactions

Drug-induced thrombocytopenia

Drug-induced thrombocytopenia (DITP) with exenatide-dependent anti-platelet antibodies has been reported in adults in the postmarketing setting. DITP is an immune-mediated reaction that is caused by drug-dependent platelet-reactive antibodies. These antibodies cause destruction of platelets in the presence of the sensitizing drug.

Hypoglycaemia

There were no events of major hypoglycaemia with Bydureon BCise in clinical studies in adults. The overall incidence of minor hypoglycaemia was 6.3%. This incidence was increased when it was used in combination with a sulphonylurea (26.1 %) compared to no sulphonylurea (0.9%) (see section 4.4). To reduce the risk of hypoglycaemia associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea may be considered (see sections 4.2 and 4.4).

When prolonged-release exenatide was added to basal insulin, no initial dose adjustment of insulin was required. Prolonged-release exenatide in combination with basal insulin showed no clinically significant differences in the incidence of hypoglycaemic episodes compared to insulin. There were no episodes of major hypoglycaemia in the prolonged-release exenatide with insulin group.

Nausea

The most frequently reported gastrointestinal adverse reaction in adults was nausea. During the controlled period of the clinical study comparing Bydureon BCise with immediate-release exenatide, nausea was reported in 9.6% and 20.5% of patients in each group. Overall, 9.3% of patients treated with Bydureon BCise reported nausea during the controlled period of both clinical studies. Most episodes of nausea were mild to moderate, associated with the initiation of treatment and decreased over time.

Injection site reactions

During the controlled period of the clinical studies in adults, injection site reactions were observed more frequently in patients treated with Bydureon BCise versus comparator-treated patients (24% versus 4% with immediate-release exenatide). These injection site reactions were generally mild and usually did not lead to discontinuation of study medication. Patients may be treated to relieve symptoms, while continuing treatment. Subsequent injections should use a different site of injection each week. In postmarketing experience with prolonged-release exenatide, cases with injection site abscesses and cellulitis have been reported.

Subcutaneous injection site nodules were observed frequently in clinical studies, consistent with the known properties of poly (D,L-lactide co-glycolide) polymer microsphere formulations. Most individual nodules did not interfere with study participation and resolved over time.

Immunogenicity

Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop antibodies to exenatide following treatment with prolonged-release exenatide.

Approximately 42% of patients developed low titre antibodies to exenatide and 32% of patients developed high titre antibodies at any time during the studies in adults. The percentage of these subjects with positive antibody titres, in particular high titres, peaked at approximately weeks 8 to 16 of dosing and then diminished over time. At the study endpoint, approximately 43% of patients had low titre antibodies to exenatide and 14% of patients had high titre antibodies. Overall, the level of glycaemic control (HbA_{1c}) in patients treated with Bydureon BCise with low titre antibodies at the last visit (-1.1% to -1.5%) was comparable to that observed in those without antibody titres (-1.1% to -1.4%). While patients with high titre

antibodies at the last visit had an attenuated HbA_{1c} response, HbA_{1c} reductions in these patients were clinically relevant (-0.6% to -0.7%).

Amongst adult patients treated with Bydureon BCise evaluable for antibodies (N = 393), the incidence of potentially immunogenic injection site reactions (most commonly injection site nodule) during the two studies was approximately 20%. These reactions were less commonly observed in antibody-negative patients (16%) and patients with low titre antibodies (16%) compared with those with high titre antibodies (27%).

Rapid weight loss

In a 30-week study in adults, approximately 3% (n = 4/148) of prolonged-release exenatide treated patients experienced at least one-time period of rapid weight loss (recorded body weight loss between two consecutive study visits of greater than 1.5 kg/week).

Increased heart rate

A mean increase in heart rate (HR) of 2.4 beats per minute (bpm) from baseline (74 bpm) was observed in the controlled period of the Bydureon BCise clinical studies in adults. Fifteen percent of prolonged-release exenatide treated patients had mean increases in HR of ≥ 10 bpm; approximately 5% to 10% of subjects within the other treatment groups had mean increases in HR of ≥ 10 bpm.

Paediatric population

The exenatide safety profile in a clinical study with adolescents and children aged 10 years or older (see section 5.1) was similar to that observed in the studies in adults.

In the paediatric study there were no major hypoglycaemia events.

During the 24-week double-blind treatment period, one patient (1.7%) in the prolonged-release exenatide group and one patient (4.3%) in the placebo group had minor hypoglycaemia (defined as a non-major hypoglycaemia event that had symptoms consistent with hypoglycaemia and a glucose value less than 3 mmol/L [54 mg/dL] prior to treating the episode). Both patients were receiving insulin as background therapy.

Other hypoglycaemia events, episodes that did not meet either major or minor criteria, were reported by the investigator in 8 patients (13.6%) and 1 patient (4.3%) in the prolonged-release exenatide and placebo groups, respectively. Out of these, 6 patients in the prolonged-release exenatide group and 1 patient in the placebo group received insulin as background therapy.

In the paediatric study the maximum antibody titre obtained at any time during the study was low (<625) for approximately 29.3% of patients and high (≥ 625) for approximately 63.8% of patients. The percentage of patients with positive antibody titres peaked at approximately Week 12. As the study continued to Week 52 the percentage of patients with high titres had decreased (30.4%) and percentage of the patients with low titres (41.3%) had increased. Patients with higher titre antibodies may have an attenuated HbA_{1c} response (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Effects of overdoses with exenatide (based on immediate-release exenatide clinical studies) included severe nausea, severe vomiting and rapidly declining blood glucose concentrations. In the event of overdose, appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes, glucagon-like peptide-1 (GLP-1) analogues, ATC code: A10BJ01.

Mechanism of action

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. Exenatide has been shown to bind to and activate the known human GLP-1 receptor *in vitro*, its mechanism of action mediated by cyclic AMP and/or other intracellular signalling pathways.

Exenatide increases, on a glucose-dependent basis, the secretion of insulin from pancreatic beta cells. As blood glucose concentrations decrease, insulin secretion subsides. When exenatide was used in combination with metformin and/or a thiazolidinedione, no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin and/or a thiazolidinedione which may be due to this glucose-dependent insulinotropic mechanism (see section 4.4).

Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in patients with type 2 diabetes. Lower glucagon concentrations lead to decreased hepatic glucose output. However, exenatide does not impair the normal glucagon response and other hormone responses to hypoglycaemia.

Exenatide slows gastric emptying, thereby reducing the rate at which meal-derived glucose appears in the circulation.

Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety.

Pharmacodynamic effects

Exenatide improves glycaemic control through the sustained effects of lowering both postprandial and fasting glucose concentrations in patients with type 2 diabetes. Unlike native GLP-1, prolonged-release exenatide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once weekly administration.

A pharmacodynamic study with exenatide demonstrated in patients with type 2 diabetes (n = 13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous bolus of glucose.

Clinical efficacy and safety

The results of two studies with Bydureon BCise and six long-term clinical studies of prolonged-release exenatide are presented below; these studies comprised 1766 adult subjects (556 treated with Bydureon BCise), 53% men and 47% women, 304 subjects (17%) were ≥ 65 years of age.

In addition, a double-blind, placebo-controlled cardiovascular outcome study (EXSCEL) enrolled 14,752 adult subjects with type 2 diabetes and any level of CV risk when added to the current usual care.

Glycaemic control

Bydureon BCise

In a 28-week open-label study in adults, Bydureon BCise was compared to immediate-release exenatide in subjects on a diet and exercise programme alone or with a stable regimen of oral glucose-lowering medicinal products. Both treatment groups had a reduction in HbA_{1c} compared to baseline. Bydureon BCise demonstrated superiority to immediate-release exenatide in reducing HbA_{1c} from baseline to Week 28 (Table 2). The 28-week comparator-controlled period of the study was followed by a 24-week extension period during which all participating subjects received treatment with this medicinal product. The effect on HbA_{1c} remained clinically significant over 52 weeks but partially diminished over time in the group that had initially received Bydureon BCise.

Both Bydureon BCise and immediate-release exenatide patients achieved a reduction in weight at Week 28 compared to baseline (Table 2). The difference between the two treatment groups was not significant. The reductions in body weight were sustained at Week 52.

Table 2: Results of one 28-week study of Bydureon BCise versus immediate-release exenatide with diet and exercise alone or with a stable regimen of oral glucose-lowering medicinal products (modified intent-to-treat patients¹)

	Bydureon BCise 2 mg QW	Immediate-release exenatide 10 mcg BID
N	229	146
Mean HbA_{1c} (%)		
Baseline	8.5	8.5
Change from baseline (\pm SE) ²	-1.4 (\pm 0.1)	-1.0 (\pm 0.1)
Mean difference in change from baseline versus immediate-release exenatide (95% CI)²	-0.37* (-0.63, -0.10)	
Patients (%) achieving HbA_{1c} < 7%³	49	43
Mean body weight (kg)		
Baseline	97	97
Change from baseline (\pm SE) ²	-1.5 (\pm 0.3)	-1.9 (\pm 0.4)
Mean difference in change from baseline versus immediate-release exenatide (95% CI)²	+0.40 (-0.48, 1.28)	
Mean change from baseline in fasting plasma glucose (mmol/L) (\pm SE)²	-1.8 (\pm 0.2)	-1.3 (\pm 0.3)
Mean difference in change from baseline	-0.56	

	Bydureon BCise 2 mg QW	Immediate-release exenatide 10 mcg BID
versus immediate-release exenatide (95% CI)²	(-1.20, 0.08)	

QW = once weekly, BID = twice daily, N = number of patients per treatment group,

SE = standard error, CI = confidence interval.

*p-value < 0.01.

¹ All randomised patients who received at least one dose of study medication.

² Least squares means.

³ Last Observation Carried Forward (LOCF).

In a 28-week open-label study (oral medication-blinded), Bydureon BCise was compared to sitagliptin and placebo in subjects also using metformin \geq 1,500 mg daily. Bydureon BCise demonstrated superiority to both sitagliptin and placebo in reducing HbA_{1c} from baseline to Week 28 (Table 3).

Both Bydureon BCise and sitagliptin patients achieved a reduction in weight at Week 28 compared to baseline (Table 3). The difference between the two treatment groups was not significant.

Table 3: Results of one 28-week study of Bydureon BCise versus sitagliptin and placebo in combination with metformin (modified intent-to-treat patients¹)

	Bydureon BCise 2 mg QW	Sitagliptin 100 mg QD	Placebo QD
N	181	122	61
Mean HbA_{1c} (%)			
Baseline	8.4	8.5	8.5
Change from baseline (\pm SE) ²	-1.1 (\pm 0.1)	-0.8 (\pm 0.1)	-0.4 (\pm 0.2)
Mean difference in change from baseline versus sitagliptin (95% CI)²	-0.38* (-0.70, -0.06)		
Mean difference in change from baseline versus placebo (95% CI)²	-0.72** (-1.15, -0.30)		
Patients (%) achieving HbA_{1c} < 7%³	43*	32	25
Mean body weight (kg)			
Baseline	89	88	89
Change from baseline (\pm SE) ²	-1.1 (\pm 0.3)	-1.2 (\pm 0.3)	+0.2 (\pm 0.5)
Mean difference in change from baseline versus sitagliptin (95% CI)²	+0.07 (-0.73, 0.87)		
Mean difference in change from baseline versus placebo (95% CI)²	-1.27 [#] (-2.34, -0.20)		
Mean change from baseline in fasting plasma glucose (mmol/L) (\pm SE)²	-1.2 (\pm 0.2)	-0.6 (\pm 0.3)	+0.5 (\pm 0.4)
Mean difference in change from baseline versus sitagliptin (95% CI)²	-0.56 (-1.21, 0.09)		
Mean difference in change from baseline versus placebo (95% CI)²	-1.71 [§] (-2.59, -0.83)		

QW = once weekly, QD = once daily, N = number of patients per treatment group, SE = standard error, CI = confidence interval.

*p-value < 0.05, **p-value < 0.01, #nominal p-value < 0.05, §nominal p-value < 0.001.

¹ All randomised patients who received at least one dose of study medication.

² Least squares means.

³ Last Observation Carried Forward (LOCF).

Prolonged-release exenatide

In two studies in adults prolonged-release exenatide 2 mg once weekly has been compared to immediate-release exenatide 5 mcg given twice daily for 4 weeks followed by immediate-release exenatide 10 mcg given twice daily. One study was of 24 weeks in duration (n = 252) and the other of 30 weeks (n = 295) followed by an open labelled extension where all patients were treated with prolonged-release exenatide 2 mg once weekly, for a further 7 years (n = 258). In both studies, decreases in HbA_{1c} were evident in both treatment groups as early as the first post-treatment HbA_{1c} measurement (Weeks 4 or 6).

Prolonged-release exenatide resulted in a statistically significant reduction in HbA_{1c} compared to patients receiving immediate-release exenatide (Table 4).

A clinically relevant effect of prolonged-release exenatide and immediate-release exenatide treated subjects was observed on HbA_{1c}, regardless of the background anti-diabetic therapy in both studies.

Clinically and statistically significantly more subjects on prolonged-release compared to immediate-release exenatide patients achieved an HbA_{1c} reduction of ≤ 7% or < 7% in the two studies (p < 0.05 and p ≤ 0.0001, respectively).

Both prolonged-release and immediate-release exenatide patients achieved a reduction in weight compared to baseline, although the difference between the two treatment arms was not significant.

In the uncontrolled study extension, evaluable patients who switched from immediate release to prolonged-release exenatide at week 30 (n = 121), achieved the same improvement in HbA_{1c} of -2.0% at Week 52 compared to baseline as patients treated with prolonged-release exenatide.

For all patients completing the uncontrolled study extension of 7 years (n = 122 of 258 patients included in the extension phase), HbA_{1c} gradually increased over time from week 52 onwards, but was still reduced compared to baseline after 7 years (-1.5%). Weight loss was sustained over 7 years in these patients.

Table 4: Results of two studies of prolonged-release versus immediate-release exenatide in combination with diet and exercise alone, metformin and/or sulphonylurea and metformin and/or thiazolidinedione (intent-to-treat patients)

24-Week Study	Prolonged-release exenatide 2 mg	Immediate-release exenatide 10 mcg twice daily
N	129	123
Mean HbA_{1c} (%)		
Baseline	8.5	8.4
Change from baseline (± SE)	-1.6 (±0.1)**	-0.9 (±0.1)
Mean difference change from baseline between	-0.67 (-0.94, -0.39)**	

24-Week Study	Prolonged-release exenatide 2 mg	Immediate-release exenatide 10 mcg twice daily
treatments (95% CI)		
Patients (%) achieving HbA_{1c} < 7%	58	30
Change in fasting plasma glucose (mmol/L) (± SE)	-1.4 (±0.2)	-0.3 (±0.2)
Mean body weight (kg)		
Baseline	97	94
Change from baseline (± SE)	-2.3 (±0.4)	-1.4 (± 0.4)
Mean difference change from baseline between treatments (95% CI)	-0.95 (-1.91, 0.01)	
30-Week Study		
N	148	147
Mean HbA_{1c} (%)		
Baseline	8.3	8.3
Change from baseline (± SE)	-1.9 (±0.1)*	-1.5 (±0.1)
Mean difference change from baseline between treatments (95% CI)	-0.33 (-0.54, -0.12)*	
Patients (%) achieving HbA_{1c} ≤ 7%	73	57
Change in fasting plasma glucose (mmol/L) (± SE)	-2.3 (±0.2)	-1.4 (±0.2)
Mean body weight (kg)		
Baseline	102	102
Change from baseline (± SE)	-3.7 (±0.5)	-3.6 (±0.5)
Mean difference change from baseline between treatments (95% CI)	-0.08 (-1.29, 1.12)	

SE = standard error, CI = confidence interval, * p < 0.05, **p < 0.0001

A study of 26-week duration has been conducted in adults, in which prolonged-release exenatide 2 mg is compared to insulin glargine once daily. Compared with insulin glargine treatment, prolonged-release exenatide demonstrated a superior change in HbA_{1c}, significantly lowered mean body weight and was associated with fewer hypoglycaemic events (Table 5).

Table 5: Results of one 26-week study of prolonged-release exenatide versus insulin glargine in combination with metformin alone or metformin and sulphonylurea (intent-to-treat patients)

	Prolonged-release exenatide 2 mg	Insulin glargine¹
N	233	223
Mean HbA_{1c} (%)		
Baseline	8.3	8.3
Change from baseline (± SE)	-1.5 (± 0.1)*	-1.3 (± 0.1)*
Mean difference change from baseline between treatments (95% CI)	-0.16 (-0.29, -0.03)*	
Patients (%) achieving HbA_{1c} ≤ 7%	62	54
Change in fasting serum glucose (mmol/L) (± SE)	-2.1 (± 0.2)	-2.8 (± 0.2)
Mean body weight (kg)		
Baseline	91	91
Change from baseline (± SE)	-2.6 (± 0.2)	+1.4 (± 0.2)
Mean difference change from baseline between treatments (95% CI)	-4.05 (-4.57, -3.52)*	

SE = standard error, CI = confidence interval, * p < 0.05

¹ Insulin glargine was dosed to a target glucose concentration of 4.0 to 5.5 mmol/L (72 to 100 mg/dL).

The mean dose of insulin glargine at the beginning of treatment was 10.1 IU/day rising to 31.1 IU/day for insulin glargine-treated patients.

The 156-week results were consistent with those previously reported in the 26-week interim report. Treatment with prolonged-release exenatide persistently significantly improved glycaemic control and weight control, compared to the insulin glargine treatment. Safety findings at 156 weeks were consistent with those reported at 26 weeks.

In a 26-week double-blind study prolonged-release exenatide was compared to maximum daily doses of sitagliptin and pioglitazone in adult subjects also using metformin. All treatment groups had a significant reduction in HbA_{1c} compared to baseline. Prolonged-release exenatide demonstrated superiority to both sitagliptin and pioglitazone with respect to change in HbA_{1c} from baseline.

Prolonged-release exenatide demonstrated significantly greater weight reductions compared to sitagliptin. Patients on pioglitazone gained weight (Table 6).

Table 6: Results of one 26-week study of prolonged-release exenatide versus sitagliptin and versus pioglitazone in combination with metformin (intent-to-treat patients)

	Prolonged-release exenatide 2 mg	Sitagliptin 100 mg	Pioglitazone 45 mg
N	160	166	165
Mean HbA_{1c} (%)			
Baseline	8.6	8.5	8.5
Change from baseline (± SE)	-1.6 (± 0.1)*	-0.9 (± 0.1)*	-1.2 (± 0.1)*
Mean difference change from baseline between treatments (95% CI) versus sitagliptin	-0.63 (-0.89, -0.37)**		
Mean difference change from baseline between treatments (95% CI) versus pioglitazone	-0.32 (-0.57, -0.06)*		
Patients (%) achieving HbA_{1c} ≤ 7%	62	36	49
Change in fasting serum glucose (mmol/L) (± SE)	-1.8 (± 0.2)	-0.9 (± 0.2)	-1.5 (± 0.2)
Mean body weight (kg)			
Baseline	89	87	88
Change from baseline (± SE)	-2.3 (± 0.3)	-0.8 (± 0.3)	+2.8 (± 0.3)
Mean difference change from baseline between treatments (95% CI) versus sitagliptin	-1.54 (-2.35, -0.72)*		
Mean difference change from baseline between treatments (95% CI) versus pioglitazone	-5.10 (-5.91, -4.28)**		

SE = standard error, CI = confidence interval, *p < 0.05, **p < 0.0001

In a 28-week, double-blind study in adults, the combination of prolonged-release exenatide and dapagliflozin was compared to prolonged-release exenatide alone and dapagliflozin alone in subjects also using metformin. All treatment groups had a reduction in HbA_{1c} compared to baseline. The prolonged-release exenatide and dapagliflozin treatment group showed superior reductions in HbA_{1c} from baseline compared to prolonged-release exenatide alone and dapagliflozin alone (Table 7).

The combination of prolonged-release exenatide and dapagliflozin demonstrated significantly greater weight reductions compared to either medicinal product alone (Table 7).

Table 7: Results of one 28-week study of prolonged-release exenatide and dapagliflozin versus prolonged-release exenatide alone and dapagliflozin alone, in combination with metformin (intent-to-treat patients)

	Prolonged-release exenatide 2 mg QW + Dapagliflozin 10 mg QD	Prolonged-release exenatide 2 mg QW + Placebo QD	Dapagliflozin 10 mg QD + Placebo QW
N	228	227	230
Mean HbA_{1c} (%)			
Baseline	9.3	9.3	9.3
Change from baseline (±SE) ^a	-2.0 (±0.1)	-1.6 (±0.1)	-1.4 (±0.1)
Mean difference in change from baseline between combination and single active medicinal product (95% CI)		-0.38* (-0.63, -0.13)	-0.59** (-0.84, -0.34)
Patients (%) achieving HbA_{1c} < 7%	45	27	19
Mean change from baseline in fasting plasma glucose (mmol/L) (±SE)^a	-3.7 (±0.2)	-2.5 (±0.2)	-2.7 (±0.2)
Mean difference in change from baseline between combination and single active medicinal product (95% CI)		-1.12** (-1.55, -0.68)	-0.92** (-1.36, -0.49)
Mean change from baseline in 2-hour postprandial plasma glucose (mmol/L) (±SE)^a	-4.9 (±0.2)	-3.3 (±0.2)	-3.4 (±0.2)
Mean difference in change from baseline between combination and single active medicinal product (95% CI)		-1.54** (-2.10, -0.98)	-1.49** (-2.04, -0.93)
Mean body weight (kg)			
Baseline	92	89	91
Change from baseline (±SE) ^a	-3.6 (±0.3)	-1.6 (±0.3)	-2.2 (±0.3)
Mean difference in change from baseline between combination and single active medicinal product (95% CI)		-2.00** (-2.79, -1.20)	-1.33** (-2.12, -0.55)

QW=once weekly, QD=once daily, SE = standard error, CI= confidence interval, N=number of patients.

^a Adjusted least squares means (LS Means) and treatment group difference(s) in the change from baseline values at Week 28 are modelled using a mixed model with repeated measures (MMRM) including treatment, region, baseline HbA_{1c} stratum (< 9.0% or ≥ 9.0%), week, and treatment by week interaction as fixed factors, and baseline value as a covariate.

*p < 0.01, **p < 0.001.

p-values are all adjusted p-values for multiplicity.

Analyses exclude measurements post rescue therapy and post premature discontinuation of study medicinal product.

In a 28-week double-blind study in adults, prolonged-release exenatide added to insulin glargine alone or with metformin was compared to placebo added to insulin glargine alone or with metformin. Insulin glargine was dosed targeting a fasting plasma glucose of 4.0 to 5.5 mmol/L (72 to 99 mg/dL). Prolonged-release exenatide demonstrated superiority to placebo in reducing HbA_{1c} from baseline to Week 28 (Table 8).

Prolonged-release exenatide was superior to placebo in reducing body weight at Week 28 (Table 8).

Table 8: Results of one 28-week study of prolonged-release exenatide versus placebo in combination with insulin glargine alone or with metformin (intent-to-treat patients)

	Prolonged-release exenatide 2 mg + Insulin glargine^a	Placebo + Insulin glargine^a
N	230	228
Mean HbA_{1c} (%)		
Baseline	8.5	8.5
Change from baseline (± SE) ^b	-1.0 (±0.1)	-0.2 (±0.1)
Mean difference in change from baseline between treatments (95% CI)	-0.74* (-0.94, -0.54)	
Patients (%) achieving HbA_{1c} ≤ 7%^c	33*	7
Mean body weight (kg)		
Baseline	94	94
Change from baseline (± SE) ^b	-1.0 (±0.3)	0.5 (±0.3)
Mean difference in change from baseline between treatments (95% CI)	-1.52* (-2.19, -0.85)	
Change from baseline in 2-hour postprandial plasma glucose (mmol/L) (± SE)^{b,d}	-1.6 (±0.3)	-0.1 (±0.3)
Mean difference in change from baseline between treatments (95% CI)	-1.54* (-2.17, -0.91)	

N=number of patients in each treatment group, SE = standard error, CI= confidence interval, *p-value < 0.001 (adjusted for multiplicity).

^a. The LS means change in mean daily insulin dose was 1.6 units for the prolonged-release exenatide group and 3.5 units for the placebo group.

^b. Adjusted LS means and treatment group difference(s) in the change from baseline values at Week 28 are modeled using a mixed model with repeated measures (MMRM) including treatment, region, baseline HbA_{1c} stratum (< 9.0% or ≥ 9.0%), baseline SU-use stratum (yes vs. no), week, and treatment by week interaction as fixed factors, and baseline value as a covariate. The absolute change in 2-hour postprandial plasma glucose at Week 28 is modeled similarly using ANCOVA.

^c. All patients with missing endpoint data are imputed as non-responders.

^d. After a standard meal tolerance test.

Analyses exclude measurements post rescue therapy and post premature discontinuation of study medication.


Cardiovascular evaluation

EXSCEL was a pragmatic cardiovascular (CV) outcome study in adult patients with type 2 diabetes and any level of CV risk. A total of 14,752 patients were randomised 1:1 to either prolonged-release exenatide 2 mg once weekly or placebo, added to the current usual care which could include SGLT2 inhibitors. Patients were followed as in routine clinical practice for a median of 38.7 months with a median treatment duration of 27.8 months. The vital status was known at the end of the study for 98.9% and 98.8% of the patients in the prolonged-release exenatide and placebo group, respectively. The mean age at study entry was 62 years (with 8.5% of the patients ≥ 75 years). Approximately 62% of the patients were male. The mean BMI was 32.7 kg/m² and the mean duration of diabetes was 13.1 years. The mean HbA_{1c} was 8.1%. Approximately 49.3% had mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 to ≤ 89 mL/min/1.73 m²) and 21.6% had moderate renal impairment (eGFR ≥ 30 to ≤ 59 mL/min/1.73 m²). Overall, 26.9% of patients did not have any prior CV event, 73.1% had at least one prior CV event.

The primary safety (noninferiority) and efficacy (superiority) endpoint in EXSCEL was the time to first confirmed Major Adverse Cardiac Event (MACE): cardiovascular (CV)-related death, nonfatal myocardial infarction (MI) or nonfatal stroke. All-cause mortality was the initial secondary endpoint assessed.


Prolonged-release exenatide did not increase the cardiovascular risk in patients with type 2 diabetes mellitus compared to placebo when added to current usual care (HR:0.91; 95% CI: 0.832, 1.004; P < 0.001 for non-inferiority) see Figure 1. In a pre-specified subgroup analysis in EXSCEL, the HR for MACE was 0.86 (95% CI: 0.77–0.97) in patients with baseline eGFR ≥ 60 mL/min/1.73 m² and 1.01 (95% CI: 0.86–1.19) in patients with baseline eGFR < 60 mL/min/1.73 m². The results of the primary composite and secondary cardiovascular endpoints are shown in Figure 2.

Figure 1: Time to First Adjudicated MACE (intent-to-treat patients)



HR=hazard ratio, CI=confidence interval

Figure 2: Forest Plot: Analysis of Primary and Secondary Endpoints (intent-to-treat patients)



ACS=acute coronary syndrome; CI=confidence interval; CV=cardiovascular; HF=heart failure; HR=hazard ratio; MACE=major adverse cardiac event; MI=myocardial infarction; n=number of patients with an event; N=number of patients in treatment group.

¹ HR (active/placebo) and CI are based on Cox proportional hazards regression model, stratified by prior CV event, with treatment group only as explanatory variable.

The need for additional antihyperglycaemic medication was reduced by 33% with the prolonged-release exenatide group (exposure-adjusted incidence of 10.5 per 100 pt-year) compared to the placebo group (exposure-adjusted incidence of 15.7 per 100 pt-year). A reduction in HbA_{1c} was observed over the course of the trial with an overall treatment difference of -0.53% (prolonged-release exenatide vs. placebo).

Body weight

A reduction in body weight compared to baseline has been observed in studies with prolonged-release exenatide formulations. This reduction in body weight was seen irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction of -1.9 kg to -5.2 kg with nausea versus -1.0 kg to -2.9 kg without nausea).

Plasma/serum glucose

Treatment with prolonged-release exenatide resulted in significant reductions in fasting plasma/serum glucose concentrations, these reductions were observed as early as 4 weeks. In the placebo-controlled study with insulin glargine, the change from baseline to Week 28 in fasting plasma glucose was -0.7 mmol/L for the prolonged-release exenatide group and -0.1 mmol/L for the placebo group. Additional reductions in postprandial concentrations were also observed.

For both prolonged-release exenatide formulations, the improvement in fasting plasma glucose concentrations was sustained through 52 weeks.

Beta-cell function

Clinical studies with prolonged-release exenatide formulations have indicated improved beta-cell function, using measures such as the homeostasis model assessments (HOMA-B). The effect on beta-cell function was sustained through 52 weeks.

Blood pressure

A reduction in systolic blood pressure was observed in the studies with prolonged-release exenatide formulations (0.8 mmHg to 4.7 mmHg). In the 30-week immediate-release exenatide comparator study both prolonged-release and immediate-release exenatide

significantly reduced systolic blood pressure from baseline (4.7 ± 1.1 mmHg and 3.4 ± 1.1 mmHg, respectively); the difference between the treatments was not significant. Improvements in blood pressure were maintained through 52 weeks.

In the placebo-controlled study with insulin glargine, the change from baseline to Week 28 in systolic blood pressure was -2.6 mmHg for the prolonged-release exenatide group and -0.7 mmHg for the placebo group.

Treatment with prolonged-release exenatide and dapagliflozin combination at Week 28 resulted in a significant mean change reduction of -4.3 ± 0.8 mmHg in systolic blood pressure compared to prolonged-release exenatide alone of -1.2 ± 0.8 mmHg ($p < 0.01$) or to dapagliflozin alone of -1.8 ± 0.8 mmHg ($p < 0.05$).

Fasting lipids

The prolonged-release exenatide formulations have shown no negative effects on lipid parameters.

Paediatric population

The efficacy and safety of prolonged-release exenatide 2 mg once weekly or placebo was evaluated in a randomized, double-blind, placebo-controlled, parallel-group study in adolescents and children aged 10 years and above with type 2 diabetes treated with diet and exercise alone or in combination with a stable dose of oral antidiabetic agents and/or insulin. The prolonged-release exenatide was superior to placebo in reducing HbA_{1c} after 24 weeks (Table 9).

Table 9: Results of one 24-week study of prolonged-release exenatide versus placebo in adolescent and paediatric patients aged 10 years and above (intent-to-treat patients)

	Prolonged-release exenatide 2 mg QW	Placebo QW
Intent-to-Treat Population (N)	58	24
Mean HbA_{1c} (%)		
Baseline	8.11	8.22
Change from baseline (\pm SE)	-0.36 (0.18)	0.49 (0.27)
Mean difference change from baseline vs. Placebo (95% CI) ^a	-0.85 (-1.51, -0.19)*	
Mean fasting plasma glucose (mmol/L)		
Baseline	9.24	9.08
Change from baseline (\pm SE)	-0.29 (0.424)	0.91 (0.63)
Mean difference change from baseline vs. Placebo (95% CI) ^b	-1.2 (-2.72, 0.32)	
Mean body weight (kg)		
Baseline	100.33	96.96
Change from baseline (\pm SE)	-0.59 (0.67)	0.63 (0.98)
Mean difference change from baseline vs. Placebo (95% CI) ^b	-1.22 (-3.59, 1.15)	
Proportion achieving HbA_{1c} <7.0%	31.0%	8.3%
Proportion achieving HbA_{1c} \leq6.5%	19.0%	4.2%
Proportion achieving HbA_{1c} <6.5%	19.0%	4.2%

*p=0.012

^a Adjusted LS mean and treatment group difference in the change from baseline values at each visit are modeled using a MMRM including treatment group, region, visit, treatment group by visit interaction, baseline HbA_{1c} and baseline HbA_{1c} by visit interaction as fixed effects, using an unstructured covariance matrix.

^b Adjusted LS mean and treatment group difference in the change from baseline values at each visit are modeled using a MMRM including treatment group, region, visit, treatment group by visit interaction, baseline value, screening HbA_{1c} (< 9.0% or ≥ 9.0%), and baseline value by visit interaction as fixed effects, using an unstructured covariance matrix.

5.2 Pharmacokinetic properties

The absorption properties of exenatide reflect the extended release properties of the prolonged-release exenatide formulation. Once absorbed into the circulation, exenatide is distributed and eliminated according to its known systemic pharmacokinetic properties (as described in this section).

Absorption

Following weekly administration of 2 mg Bydureon BCise, mean exenatide concentrations exceeded minimal efficacious concentrations (~ 50 pg/mL) in 2 weeks with gradual increase in the average plasma exenatide concentration up to Week 8. Subsequently, exenatide concentrations of approximately 153-208 pg/mL were maintained, indicating that steady state was achieved. Steady-state exenatide concentrations are maintained during the one-week interval between doses with minimal peak to trough fluctuation from this average therapeutic concentration.

Distribution

The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is 28 L.

Biotransformation and elimination

Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. The mean apparent clearance of exenatide is 9 L/h. These pharmacokinetic characteristics of exenatide are independent of the dose. Approximately 10 weeks after discontinuation of prolonged-release exenatide therapy, mean plasma exenatide concentrations fell below minimal detectable concentrations.

Special populations

Renal impairment

No clinically meaningful differences were observed in steady state exenatide concentrations or tolerability in patients with mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73m²) receiving Bydureon BCise, compared to those with normal renal function.

Hepatic insufficiency

No pharmacokinetic study has been performed in patients with hepatic insufficiency. Exenatide is cleared primarily by the kidney; therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide.

Gender, race and body weight

Gender, race and body weight have no clinically relevant influence on exenatide pharmacokinetics.

Elderly

Data in elderly are limited, but suggest no marked changes in exenatide exposure with increased age up to about 75 years old.

In a pharmacokinetic study of immediate-release exenatide in patients with type 2 diabetes, administration of exenatide (10 mcg) resulted in a mean increase of exenatide AUC by 36% in 15 elderly subjects aged 75 to 85 years compared to 15 subjects aged 45 to 65 years likely related to reduced renal function in the older age group (see section 4.2).

Paediatric population

The population pharmacokinetic analysis in adolescents and children with low ADA titre aged 10 years and above with type 2 diabetes mellitus demonstrated that administration of prolonged-release exenatide (2 mg) resulted in exposure similar to that observed in adults.

5.3 Preclinical safety data

Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity conducted with immediate-release or prolonged-release exenatide.

Thyroid tumours have been observed in rats and mice with long acting GLP-1 receptor agonists. In a 2-year rat carcinogenicity study with prolonged-release exenatide, an increased incidence of C-cell adenomas and C-cell carcinomas was observed at doses \geq 2-fold the human systemic exposure based on AUC. The clinical relevance of these findings is currently unknown.

Animal studies with exenatide did not indicate harmful effects with respect to fertility; high doses of exenatide caused skeletal effects and reduced foetal and neonatal growth.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Powder

poly (D,L-lactide-co-glycolide)
sucrose

Vehicle

Medium chain triglycerides

6.2 Incompatibilities

In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

3 years

After suspension

The suspension must be injected immediately after mixing the powder and the solvent.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

The pens may be kept for up to 4 weeks below 30 °C prior to use.

Store in the original package in order to protect from light.

The pens must be stored flat.

6.5 Nature and contents of container

The suspension is packaged in a 2-mL Type I glass cartridge, sealed at one end with a (bromobutyl) rubber seal/cap combination (combiseal), and at the other end with a (bromobuty) rubber plunger. The finished medicinal product is comprised of the suspension-filled cartridge assembled into the pen device.

The pen contains an integrated needle.

Pack size of 4 single-dose pre-filled pens (BCise) and a multipack containing 12 (3 packs of 4) single-dose pre-filled pens (BCise).

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Pre-filled pen is for single-use only.

The pen must be removed from the refrigerator for at least 15 minutes prior to injection. The powder in one chamber must be mixed with the solvent in the other chamber of the pre-filled pen. The solvent should be visually inspected prior to use. The solvent should only be used if it is clear and free of particulate matter. After suspension, the mixture should only be used if it is white to off white and cloudy. Please see the package leaflet and “Instructions for the User” for additional information on suspension and administration.

Use only the supplied custom needles with the pen.

Prolonged-release exenatide must be injected subcutaneously immediately after mixing of the powder and the solvent.

Prolonged-release exenatide that has been frozen must not be used.

The patient should be instructed to discard the pen safely, with the needle still attached, after each injection.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

AstraZeneca UK Limited,
1 Francis Crick Avenue,
Cambridge,
CB2 0AA,
UK.

8 MARKETING AUTHORISATION NUMBER(S)

PLGB 17901/0315

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 1 January 2021

Date of latest renewal: 18 February 2016

10 DATE OF REVISION OF THE TEXT

05/06/2024